field
viroporin
born
year
ago
realiz
virus
inflict
injuri
membran
cell
infect
result
increas
membran
permeabl
carrasco
earli
observ
herald
current
interest
viroporin
along
therapeut
opportun
afford
modul
channel
activ
use
small
molecul
fischer
wang
schindler
chen
scott
griffin
deeper
understand
role
viroporin
ion
channel
activ
viral
replic
pathogenesi
nietotorr
verdiabaguena
castanorodriguez
aguilella
enjuan
interest
like
increas
discoveri
new
viroporin
along
evergrow
role
viru
life
cycl
inde
number
medic
import
viroporin
known
expect
rise
new
human
virus
continu
emerg
anim
host
also
possibl
new
viroporin
may
novel
featur
structur
motif
contribut
updat
classif
term
topolog
number
transmembran
domain
nieva
madan
carrasco
vertebr
alon
number
virus
estim
around
one
million
mors
recent
estim
quantifi
viral
divers
mammal
reservoir
host
major
emerg
zoonos
anthoni
et
al
strongli
contrast
thousand
virus
identifi
date
mean
virusesand
viroporin
anyar
still
unknown
viroporin
identifi
virul
factor
lead
viral
attenu
delet
attenu
attribut
part
channel
activ
nevertheless
smallmolecul
channel
inhibitor
sought
vast
major
channel
inhibitor
develop
influenza
viru
iav
protein
review
recent
du
cross
zhou
gu
liu
wei
first
viroporin
discov
surpris
sinc
best
character
viroporin
date
wellestablish
biolog
role
viral
pathogenesi
combin
extens
structur
investig
conduct
emerg
valid
drug
target
viroporin
studi
still
mostli
infanc
although
highresolut
structur
hepat
c
viru
hcv
protein
recent
describ
ouyang
et
al
may
use
ration
design
channel
inhibitor
futur
howev
attempt
ration
design
smallmolecul
inhibitor
viroporin
encount
sever
challeng
one
potenti
sequenc
variabl
viroporin
inde
argu
sinc
number
gene
suscept
deleteri
mutat
increas
genom
size
mutat
rate
higher
small
genom
drake
relat
problem
viral
protein
compar
prokaryot
eukaryot
protein
higher
degre
structur
flexibl
may
repres
adapt
mechan
increas
resist
random
mutat
especi
case
rna
virus
mutat
evolv
faster
dna
virus
less
dens
pack
concomit
smaller
number
network
interact
translat
smaller
differ
energi
fold
unfold
state
also
smaller
percentu
contribut
mutat
stabil
tokuriki
oldfield
uverski
berezovski
tawfik
addit
enhanc
flexibl
may
impact
abil
singl
protein
perform
varieti
task
consist
econom
use
resourc
virus
ad
intrins
flexibl
anoth
problem
structurebas
drug
discoveri
concern
viroporin
strong
depend
protein
structur
environ
inde
solut
nmr
appli
studi
smallmembran
protein
membranemimick
environ
allow
rapid
reorient
artifici
system
may
also
alter
intrins
properti
protein
cross
dong
sharma
busath
zhou
cross
sharma
yi
zhou
last
viroporin
seem
form
proteinlipid
complex
rather
pure
proteinac
pore
shown
protein
triatoma
viru
sanchezeugenia
goikolea
gilcarton
sanchezmagran
guerin
similar
observ
also
report
coronaviru
envelop
protein
verdiabaguena
et
al
quest
discov
small
molecul
target
viroporin
amantadin
amt
consid
first
viroporin
channel
inhibitor
one
first
antivir
licens
use
human
although
known
adamantan
activ
iav
davi
et
al
wingfield
pollack
grunert
mechan
inhibit
describ
duff
ashley
pinto
holsing
lamb
target
known
hay
wolstenholm
skehel
smith
even
today
amt
togeth
methyl
deriv
rimantadin
rim
licens
licens
antivir
drug
target
viroporin
contrast
avail
hundr
compound
exert
effect
subnanomolar
affin
nonvir
ion
channel
although
phenomenon
could
explain
principl
lack
structur
data
viroporin
case
precis
structur
data
obtain
even
amtresist
mutant
wang
qiu
soto
degrado
unfortun
effect
altern
adamantan
yet
licens
current
knowledg
channel
provid
yet
anoth
paradigm
valid
viroporin
simpl
structur
compar
ion
channel
higher
organ
k
ca
channel
mechan
proton
conduct
drug
bind
inhibit
yet
fulli
understood
inde
structur
function
properti
protein
vari
wide
chang
experiment
condit
peptid
length
drug
bind
lipid
composit
lipid
thick
ph
acharya
et
al
cadi
wang
hong
cross
et
al
kovac
denni
song
quin
cross
thomaston
et
al
zhou
cross
import
factor
sensit
direct
contact
tm
domain
lipid
molecul
contrast
higher
organ
ion
channel
eg
k
channel
cuello
jogini
cort
perozo
poreform
surround
protect
addit
transmembran
helic
howev
channel
exist
varieti
conform
state
apoform
inhibitorbind
significantli
reduc
conform
flexibl
channel
structur
dynam
channel
repres
anoth
drawback
use
highresolut
structur
ration
design
drug
discoveri
amantadin
one
four
antivir
iav
avail
two
neuraminidas
inhibitor
oseltamivir
zanamivir
two
channel
blocker
amt
rim
vanderlinden
naesen
season
flu
caus
iav
associ
high
medic
burden
molinari
et
al
sudden
pandem
high
mortal
rate
hay
gregori
dougla
yi
neumann
noda
kawaoka
current
circul
strain
amt
resist
bright
shay
shu
cox
klimov
bright
et
al
deyd
et
al
hayden
de
jong
therefor
use
amt
rim
discontinu
human
popul
fior
et
al
channel
homotetram
sakaguchi
tu
pinto
lamb
monom
amino
acid
contain
one
tm
domain
residu
extramembran
ctermin
domain
residu
expos
cytoplasm
side
lamb
zebede
richardson
contain
amphipath
helix
residu
four
amphipath
helic
stabil
tetramer
channel
form
base
membran
surfac
almost
perpendicular
tm
bundl
end
ctermin
tail
disord
interact
viral
matrix
protein
protein
perform
sever
critic
role
viru
replic
pinto
lamb
instanc
acidif
interior
viru
requir
uncoat
genet
materi
insid
cell
pinto
et
al
also
requir
regul
intralumen
ph
golgi
apparatu
prevent
prematur
conform
chang
hemagglutinin
takeuchi
lamb
influenza
b
closest
rel
influenza
viru
account
influenza
diseas
recent
year
accord
us
center
diseas
control
prevent
websit
wwwcdcgov
similarli
essenti
phactiv
proton
channel
viroporin
hatta
goto
kawaoka
pinto
lamb
although
share
almost
sequenc
ident
singl
tm
domain
form
homotetram
wang
pielak
mcclintock
chou
comparison
complet
insensit
amt
rim
mould
et
al
pinto
lamb
inhibitor
identifi
yet
locat
bind
site
adamantan
amt
rim
initi
controversi
crystallograph
structur
suggest
porebind
model
aminotermin
part
tm
ie
pbind
site
stouffer
et
al
fig
c
follow
year
solut
nmrbase
structur
longer
construct
pielak
schnell
chou
schnell
chou
propos
surfacebind
site
sbind
site
rim
carboxytermin
lipidfac
surfac
helic
fig
suggest
altern
alloster
mechan
inhibit
alloster
bind
site
adamantan
group
interact
favour
hydrophob
side
chain
wherea
posit
charg
ammonium
group
interact
polar
patch
form
figur
pand
sbind
site
amt
rim
iav
ac
tm
domain
crystal
deterg
critic
residu
identifi
sitedirect
mutagenesi
line
pore
omit
map
show
electron
densiti
amt
bind
region
b
structur
amantadin
nitrogen
cyan
light
gray
print
version
carbon
white
insid
bind
site
show
surfac
associ
residu
red
light
gray
print
version
surfac
green
dark
gray
print
version
blue
light
gray
print
version
orang
light
gray
print
version
c
e
ensembl
lowenergi
structur
deriv
nmr
restraint
tm
residu
amphipath
helic
residu
superimpos
separ
ribbon
represent
show
drug
rim
color
red
light
gray
print
version
e
f
g
surfac
represent
rimbind
pocket
show
indol
amin
form
polar
patch
well
hydrophob
wall
compos
solut
nmr
structur
tm
channel
absenc
presenc
rim
ensembl
lowenergi
structur
drugbound
chimera
channel
rim
highlight
red
light
gray
print
version
h
ribbon
represent
drugfre
tm
tetram
left
overlay
region
green
dark
gray
print
version
correspond
region
yellow
light
gray
print
version
pdb
code
pdb
code
structur
right
overlay
drugfre
white
drugbound
cyan
light
gray
print
version
chimera
structur
show
substanti
differ
helic
pack
j
adapt
permiss
macmillan
publish
ltd
stouffer
l
acharya
r
salom
levin
di
costanzo
l
soto
c
et
al
adjac
subunit
fig
dilemmat
featur
alloster
site
viral
mutat
site
easili
accommod
virus
without
dramat
loss
fit
hcv
exampl
proteas
inhibitor
monotherapi
rapidli
select
resist
viral
popul
within
day
schmidt
et
al
howev
clear
support
pbind
site
obtain
solidst
nmr
lipid
bilay
pdb
id
cadi
et
al
inhibitor
found
hydrophil
pocket
form
ie
occlud
channel
case
hydrophob
interact
detect
adamantan
group
side
chain
wherea
ammonium
group
hydrogenbond
porefac
residu
water
molecul
latter
work
reveal
sbind
site
fact
lowaffin
site
observ
high
concentr
drug
membran
importantli
amt
found
undergo
signific
motion
ntermin
lumen
suggest
structur
improv
better
fit
channel
poreloc
pbind
also
valid
chou
et
al
solut
nmr
pielak
oxenoid
chou
use
chimer
sampl
ntermin
part
tm
domain
correspond
wherea
ctermin
part
amtinsensit
fig
j
model
methyl
group
four
subunit
form
hydrophob
pocket
around
adamantan
amino
group
polar
contact
backbon
oxygen
end
controversi
accept
initi
propos
pbind
site
structur
wildtyp
drugresist
mutant
channel
avail
protein
data
bank
solv
differ
techniqu
condit
see
summari
gu
et
al
among
structur
solv
micel
schnell
chou
structur
bilay
environ
contain
addit
tm
domain
short
ctermin
intracellular
amphipath
helic
ctermin
helic
connect
transmembran
helic
via
short
loop
residu
expos
solut
howev
ctermin
helic
connect
tm
helic
rigid
turn
residu
posit
bilay
surfac
sharma
et
al
conform
stabil
extens
hydrophob
interact
among
helic
polar
residu
buri
hydrophob
residu
intracellular
amphipath
helic
make
sbind
site
hydrophob
micel
therefor
sbind
site
absent
sharma
et
al
molecular
dynam
simul
proton
channel
inhibitor
bind
differ
site
shown
pbind
site
stabl
drug
bind
higher
energi
barrier
need
overcom
bind
occur
gu
et
al
sbind
site
less
stabl
drug
bind
nearli
barrier
less
easili
access
therefor
pbind
site
repres
thermodynam
bind
site
drug
molecul
bind
slowli
stabli
dissoci
even
slowli
wherea
sbind
site
kinet
bind
site
drug
molecul
bind
readili
less
stabli
dissoci
easili
last
four
decad
systemat
studi
amantadin
analogu
librari
screen
elucid
structureact
relationship
sar
help
identifi
potent
wildtyp
wt
channel
blocker
de
clercq
lagoja
de
clercq
sever
molecul
base
adamantan
exampl
spiren
guanidin
analogu
undecanol
fig
discov
highthroughput
screen
base
abil
inhibitor
revers
toxic
associ
channel
express
yeast
saccharomyc
cerevisia
kurtz
et
al
base
nonadamantan
sar
studi
use
combin
viral
plaqu
assay
twoelectrod
voltag
clamp
tevc
wang
cadi
et
al
gener
undecan
hydrochlorid
fig
lack
wang
cadi
et
al
imidazolin
group
compound
show
ic
ae
ie
order
magnitud
potent
amantadin
ic
increas
potenc
rel
parent
compar
amt
spiropiperidin
induc
homogen
conform
peptid
reduc
dynam
disord
near
waterfil
central
caviti
helic
bundl
suggest
extens
bind
channel
thu
lead
stronger
inhibitori
potenc
howev
compound
effect
wildtyp
crucial
current
preval
amtresist
variant
eg
compris
report
resist
mutant
furus
suzuki
oshitani
suzuki
et
al
three
mutat
one
known
origin
drug
select
pressur
furus
et
al
mutant
one
among
three
complet
resist
amt
rim
hand
found
mutat
channel
iav
subtyp
virus
bright
et
al
caus
time
decreas
ic
low
micromolar
amt
mm
rim
first
nonadamantan
inhibitor
mutant
polycycl
pyrrolidin
dual
inhibitor
wt
ic
ic
reycarrizo
et
al
later
compound
tripl
inhibitor
efficaci
report
author
activ
wt
mutant
ic
respect
reycarrizo
et
al
inhibitori
activ
compound
test
channel
express
xenopu
laevi
oocyt
use
twoelectrod
voltag
clamp
tevc
techniqu
compound
cytotox
amt
rim
test
cellbas
antivir
plaqu
reduct
assay
therefor
despit
encourag
result
obtain
vitro
toxic
properti
compound
still
hinder
therapeut
potenti
spiropiperidin
inspir
gener
anoth
compound
fig
could
inhibit
wt
ic
also
mutant
ic
ic
wang
fiorin
et
al
direct
interact
compound
mutant
assess
solidst
nmr
inhibit
demonstr
plaqu
reduct
assay
compound
howev
inact
mutant
observ
ration
fact
mutant
dynam
hydrat
pore
correspond
wt
protein
shown
nmr
studi
lead
disrupt
size
polar
pore
precis
region
accommod
adamantan
group
therebi
hamper
discoveri
inhibitor
led
attempt
increas
polar
dimens
adamantan
core
order
captur
interact
backbon
channel
varieti
scaffold
use
substitut
hydrophob
adamantan
group
hu
et
al
wang
balannik
et
al
compound
show
excel
activ
wt
highli
activ
wang
fiorin
et
al
howev
none
better
amt
attempt
introduc
addit
group
amin
enhanc
affin
wt
via
addit
electrostat
interact
led
discoveri
benzylsubstitut
amantadin
deriv
fig
dual
wt
inhibitor
ic
wt
respect
degrado
group
later
discov
smallmolecul
drug
eg
lock
dynam
mutant
welldefin
conform
enabl
highresolut
structur
determin
solut
nmr
show
drug
bound
homotetramer
channel
thread
side
chain
compound
form
conjug
group
amin
amt
fig
f
ic
inhibit
potenc
greater
amt
charg
ammonium
bind
hydrat
one
three
site
align
along
central
caviti
might
stabil
hydroniumlik
speci
form
proton
diffus
outer
channel
protonshuttl
residu
near
cytoplasm
end
channel
e
f
compound
ic
g
compound
found
wu
et
al
base
structur
molecular
dynam
data
degrado
group
realiz
inhibitor
activ
wt
channel
bind
opposit
orient
aromat
headgroup
face
toward
cterminu
wt
toward
nterminu
investig
substitut
led
identif
halidesubstitut
thiophen
compound
potent
n
methyl
fig
inhibit
wt
mutant
compar
affin
amt
wt
wu
et
al
would
desir
develop
paradigm
found
iav
inhibitor
viroporin
channel
inhibitor
valid
exampl
mani
amantadineresist
influenza
virus
select
cell
cultur
gramba
bennett
hay
hay
et
al
also
found
infect
patient
undergo
treatment
amantadin
shiraishi
et
al
turn
engin
virus
harbor
porelin
mutat
compet
replic
mous
abe
goyett
boivin
give
rise
attenu
virus
tend
revert
wt
absenc
drug
pressur
suzuki
et
al
anoth
import
viroporin
found
hepat
c
viru
hcv
member
flavivirida
famili
six
genotyp
gt
hcv
positivestrand
rna
viru
caus
sever
liver
diseas
major
caus
hepatocellular
carcinoma
develop
world
hcv
chronic
infect
million
peopl
worldwid
respons
yearli
death
prophylact
therapeut
vaccin
avail
hcv
infect
cure
drug
target
viral
enzym
protein
well
host
cellular
protein
one
hosttarget
antivir
agent
hta
type
hoofnagl
et
al
exert
antivir
activ
rna
dna
virus
ifnstimul
gene
isg
product
pegyl
ifn
use
combin
ribavirin
rbv
synthet
guanosin
analogu
herrmann
lee
marino
modi
zeuzem
antivir
therapi
last
year
associ
side
effect
alway
effect
mann
wedemey
cornberg
pawlotski
chevaliez
mchutchison
drug
target
hcv
protein
high
potenc
hcv
proteas
protein
rnadepend
rna
polymeras
rdrp
sulkowski
et
al
see
pawlotski
schmidt
et
al
recent
review
howev
drug
resist
creat
burden
patient
worsen
rapid
turnov
hcv
replic
produc
virion
daili
neumann
et
al
compound
errorpron
activ
hcv
rna
polymeras
lead
high
genet
divers
hcv
format
quasispeci
complic
context
clinic
nich
inhibitor
unclear
viroporin
hcv
encod
within
singl
polyprotein
precursor
simmond
process
host
viral
proteas
moradpour
penin
separ
structur
protein
core
envelop
glycoprotein
nonstructur
protein
lindenbach
rice
result
cleavag
signal
peptidas
er
lin
lindenbach
mccourt
rice
mizushima
et
al
protein
residu
long
two
tm
domain
found
mainli
er
membran
although
necessari
rna
replic
lohmann
et
al
essenti
product
hcv
propag
vivo
howev
precis
role
viru
product
determin
possibl
replic
genotyp
isol
japanes
patient
suffer
fulmin
hepat
design
kato
et
al
wakita
et
al
isol
effici
replic
human
hepatoma
cell
line
produc
infecti
viru
particl
use
demonstr
essenti
viru
particl
assembl
releas
jone
murray
eastman
tassello
rice
steinmann
et
al
bovin
viral
diarrhea
viru
bvdv
harada
tautz
thiel
hepaciviru
gb
viru
b
gbvb
takikawa
et
al
hcv
closest
rel
also
protein
crucial
viru
replic
channel
activ
examin
year
ago
experi
involv
artifici
lipid
bilay
suggest
prefer
cation
vs
anion
permeabl
ratio
rang
griffin
et
al
montserret
et
al
premkumar
wilson
ewart
gage
pavlov
et
al
recent
xenopu
oocyt
ouyang
et
al
select
rather
low
compar
channel
eg
cystic
fibrosi
transmembran
conduct
regul
cftr
cl
channel
select
anion
cation
anderson
et
al
bear
et
al
potassium
channel
conduct
k
ion
near
diffus
limit
select
k
na
doyl
et
al
aquaporin
water
ion
flux
ratio
pohl
howev
biolog
import
cation
channel
activ
may
rel
light
recent
found
role
permeabil
membran
proton
act
prevent
acidif
intracellular
vesicl
wozniak
et
al
proton
channel
activ
found
crucial
product
infecti
virus
observ
intracellular
vesicl
harbor
recent
proton
channel
activ
directli
confirm
vitro
use
purifi
nontag
protein
liposomebas
assay
gan
surya
vararattanavech
torr
lipid
composit
use
mixtur
paesc
pape
pspc
ww
gervai
et
al
sever
initi
paper
also
report
inhibit
channel
activ
compound
exampl
histag
genotyp
inhibit
amantadin
griffin
et
al
wherea
synthet
genotyp
strain
inhibit
hexamethyleneamilorid
hma
fig
although
peptid
larg
unpurifi
premkumar
et
al
anoth
synthet
also
unpurifi
inhibit
longalkylchain
imino
sugar
deriv
nndgj
nndnj
fig
pavlov
et
al
howev
channel
activ
purifi
synthet
hcvj
genotyp
artifici
lipid
bilay
inhibit
presenc
hma
wherea
amt
show
effect
even
mm
concentr
montserret
et
al
fact
efficaci
amt
hcv
cultur
system
low
steinmann
et
al
clinic
benefit
amtbas
combin
therapi
found
comparison
standard
care
plu
ribavirin
castelain
et
al
mihm
et
al
compound
studi
infect
cell
reduc
viru
product
genotypedepend
manner
foster
et
al
gottwein
et
al
steinmann
et
al
reduc
secret
hcv
particl
inhibit
acidif
viruscontain
compart
wozniak
et
al
without
impair
infect
intracellular
virion
foster
et
al
griffin
et
al
discov
channel
inhibitor
liposomebas
dye
carboxyfluorescein
cf
releas
assay
propos
involv
addit
protein
preload
liposom
stgelai
et
al
method
claim
sensit
inhibitor
amt
rim
propos
highthroughput
function
assay
test
drug
sensit
mutant
discov
new
channel
activ
inhibitor
foster
et
al
gervai
et
al
dye
releas
assay
previous
perform
tag
protein
either
flag
li
et
al
stgelai
et
al
fluantigen
foster
et
al
howev
method
put
question
sinc
ctermin
half
effici
fulllength
releas
cf
properli
reconstitut
sampl
abl
elicit
cf
releas
gan
et
al
nevertheless
inhibitor
may
abl
inhibit
proton
channel
activ
dye
releas
mechan
similar
eg
via
alloster
effect
increas
rigid
ctermin
half
support
fact
interact
amt
site
inhibit
adamantan
inde
amt
interact
leucin
leucin
shown
unequivoc
part
membran
insert
cook
opella
ouyang
et
al
bind
amt
dihexanoylphosphatidylcholin
dhpc
micel
led
reson
shift
sever
residu
leucin
ie
locat
cook
opella
consist
leu
ala
mutat
region
produc
amtresist
mutant
reveal
use
cf
releas
assay
stgelai
et
al
imino
sugar
nndnj
rim
inhibit
secret
infect
amtresist
virus
wherea
mutat
confer
resist
rimantadin
foster
et
al
consist
rim
resist
found
patient
respond
tripl
therapi
ifnribamt
mihm
et
al
use
oligomer
assay
dhpc
gel
oligomer
abolish
presenc
iminosugar
wherea
rim
affect
oligomer
suggest
two
differ
mechan
action
two
compound
foster
et
al
found
resist
nndnj
vitro
cultur
attribut
mutat
foster
et
al
griffin
et
al
howev
direct
interact
hma
imino
sugar
deriv
reconstitut
deterg
membran
report
addit
rim
monom
methanol
foster
et
al
show
disrupt
sever
residu
especi
thu
observ
either
inconsist
propos
role
acquir
resist
methanol
environ
good
system
test
interact
structur
data
obtain
initi
solvent
micel
solut
nmr
exampl
solut
nmr
data
obtain
synthet
mutant
helix
induc
trifluoroethanol
tfe
montserret
et
al
recombin
mutant
dhpc
micel
preval
model
monom
accord
studi
hairpin
two
tm
kink
middl
cook
zhang
park
wang
opella
montserret
et
al
ntermin
tm
helix
would
face
lumen
channel
carrerekrem
et
al
chew
vijayan
chang
zitzmann
biggin
patargia
zitzmann
dwek
fischer
form
either
six
seven
monom
clark
et
al
griffin
et
al
luik
et
al
montserret
et
al
recent
publish
structur
model
ouyang
et
al
oligomer
size
still
ambigu
sinc
data
could
obtain
environ
use
electron
microscopi
model
old
domain
would
correspond
three
helic
segment
ie
first
half
second
half
concern
howev
model
present
physiolog
context
sinc
fold
impli
difficult
explain
current
understand
protein
fold
cell
madan
bartenschlag
ouyang
et
al
paper
author
systemat
test
amino
acid
sequenc
variou
hcv
genotyp
found
sequenc
strain
gener
sampl
adequ
structur
determin
although
oligomer
size
dodecyl
phosphocholin
dpc
micel
determin
combin
data
neg
stain
electron
microscopi
em
show
hexamer
flowershap
particl
latter
similar
hexam
observ
em
presenc
dhpc
micel
use
earlier
singleparticl
reconstruct
luik
et
al
nmrbase
model
show
ctermin
helix
porelin
sequenc
instead
form
lipid
face
part
molecul
wherea
ntermin
half
would
orient
line
lumen
ouyang
et
al
agreement
previou
model
base
partial
inhibit
channel
activ
cu
mg
suggest
exposur
residu
locat
ntermin
half
lumen
channel
although
interpret
may
correct
unfortun
synthet
peptid
correspond
ntermin
half
eg
ctermin
half
eg
aggreg
easili
individu
channel
activ
peptid
properli
measur
montserret
et
al
fact
neither
helic
separ
form
structur
micel
membran
peptid
total
insolubl
tfe
deterg
gan
et
al
difficulti
also
encount
ntermin
fragment
montserret
et
al
contrast
tm
domain
viroporin
complet
eg
iav
torr
kukol
arkin
sever
acut
respiratori
syndrom
coronaviru
sarscov
e
respiratori
syncyti
viru
rsv
sh
gan
et
al
produc
sharp
amid
band
infrar
spectrum
consist
nevertheless
amt
bind
site
channel
determin
identifi
nuclear
overhaus
enhanc
noe
protein
backbon
amid
proton
drug
proton
ouyang
et
al
fig
although
fullscal
structur
determin
complex
could
achiev
amt
mm
show
noe
crosspeak
adamantan
proton
amid
proton
ie
poreform
peripher
helic
suggest
pocket
form
polar
amino
group
amt
point
channel
lumen
similar
result
also
obtain
rim
amt
rim
also
report
previous
interact
residu
ntermin
half
cook
opella
stgelai
et
al
isotherm
titrat
calorimetri
nmr
chemic
shift
perturb
analys
rim
interact
produc
bind
constant
kd
mm
deterg
concentr
author
propos
larg
differ
drug
efficaci
observ
differ
hcv
genotyp
probabl
due
variat
hydrophob
bind
pocket
among
variant
adamantan
deriv
inhibit
channel
activ
restrict
structur
rearrang
channel
ie
alloster
mechan
perhap
effici
effect
inhibitor
report
n
guanidin
fig
amilorid
identifi
bacteri
assay
involv
express
e
coli
presenc
inhibitor
normal
ionic
gradient
maintain
cell
abl
grow
despit
presenc
compound
antivir
activ
hcv
model
pestiviru
bovin
viral
diarrhea
viru
bvdv
ic
nm
addit
block
ion
channel
activ
synthet
hcv
protein
although
data
report
context
hcv
infect
dock
effort
perform
bichmann
wang
fischer
direct
interact
proven
use
biophys
structur
assay
therefor
ration
optim
compound
still
possibl
addit
hcv
human
immunodefici
viru
hiv
viroporin
vpu
also
target
test
vpu
tm
domain
use
black
lipid
membran
blm
system
target
expos
drug
khouri
ewart
luscomb
miller
wilkinson
although
direct
interact
vpu
observ
assum
sinc
drug
activ
vpu
gene
one
earli
clinic
trial
phase
ibiia
involv
treatment
hcv
patient
indic
signific
reduct
viral
load
week
treatment
combin
wwwbiotroncomau
biotron
current
phase
clinic
trial
progress
first
result
indic
activ
sever
hcv
genotyp
includ
difficulttotreat
wwwbiotroncom
au
may
sinc
also
activ
vpu
might
suitabl
treatment
hcvhiv
coinfect
patient
jul
updat
dose
trial
recommend
futur
trial
would
focu
patient
infect
hcv
studi
combin
directact
antivir
drug
trial
patient
receiv
mg
twice
daili
month
phase
trial
hcv
demonstr
patient
infect
hcv
receiv
mg
combin
current
standard
care
therapi
ifnrbv
undetect
viru
week
phase
trial
hivhcv
coinfect
patient
show
hcv
patient
complet
day
treatment
combin
ifnrbv
undetect
hcv
load
week
sustain
viral
respons
complet
therapi
also
develop
treatment
hiv
pioneer
new
class
antivir
drug
may
provid
new
approach
erad
viru
shown
clinic
efficaci
hiv
reservoir
cell
potenti
combin
new
exist
antiretrovir
drug
erad
longliv
pool
viru
success
elimin
current
treatment
despit
promis
result
howev
remain
demonstr
target
vpu
infect
cell
studi
viroporin
coronavirus
envelop
e
protein
coronavirus
cov
typic
affect
respiratori
tract
gut
mammal
bird
cov
belong
subfamili
coronavirina
famili
coronavirida
organ
four
genera
enjuan
et
al
approxim
common
cold
caus
two
human
particular
medic
interest
viru
respons
sever
acut
respiratori
syndrom
sar
produc
near
pandem
holm
recent
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
year
caus
hundr
death
raj
osterhau
fouchier
haagman
coronaviru
viroporin
eg
lu
et
al
acid
protein
three
put
tm
domain
also
attract
increas
interest
chien
et
al
hsu
fischer
inhibitor
structur
data
avail
far
current
effect
licens
treatment
exist
coronaviru
infect
kilianski
baker
kilianski
mielech
deng
baker
lou
sun
rao
although
live
vaccin
consist
attenu
virus
promis
strategi
enjuan
nietotorr
jimenezguardeno
dediego
graham
et
al
along
fusion
inhibitor
review
healdsarg
gallagh
even
possibl
reappear
virul
phenotyp
drug
side
effect
resist
call
continu
antivir
develop
envelop
e
protein
residu
long
one
tm
domain
li
surya
claudin
torr
parthasarathi
et
al
parthasarathi
et
al
pervushin
et
al
torr
et
al
torr
wang
parthasarathi
liu
cytoplasm
ctermin
domain
lumen
nterminu
cors
macham
nietotorr
et
al
raamsman
et
al
ruch
macham
cov
e
protein
present
low
concentr
virion
cors
macham
godet
lharidon
vautherot
laud
liao
yuan
torr
tam
liu
yu
bi
weiss
leibowitz
found
abundantli
intern
membran
infect
host
cors
macham
liao
et
al
raamsman
et
al
tung
et
al
eg
ergolgi
intermedi
compart
ergic
virion
assembl
lopez
riffl
pike
gardner
hogu
nietotorr
et
al
cov
e
protein
found
critic
viral
pathogenesi
protect
antiapoptot
effect
infect
cell
may
help
viru
evad
prematur
death
host
cell
therebi
allow
viral
replic
interestingli
delet
e
protein
reduc
pathogen
mortal
anim
model
reduc
inflamm
dediego
et
al
discuss
laterand
led
develop
live
attenu
vaccin
base
edelet
etrunc
virion
et
al
lamirand
et
al
netland
et
al
structur
data
avail
cov
e
protein
sarscov
e
tm
domain
etm
character
detail
lipid
membran
later
solut
nmr
select
label
synthet
etm
residu
dpc
micel
produc
similar
pentamer
lefthand
parallel
bundl
pervushin
et
al
model
face
lumen
channel
wherea
involv
helixhelix
interact
subunit
pervushin
et
al
mutat
residu
abolish
channel
activ
vitro
torr
et
al
introduct
mutat
recombin
sarscov
result
vivo
attenu
mous
model
integr
tm
domain
preserv
channel
activ
shown
import
inflammasom
activ
elev
product
proinflammatori
cytokin
nieto
studi
revert
mutant
channelinact
e
regain
fit
pathogen
also
regain
channel
activ
measur
black
lipid
membran
etm
fulllength
e
protein
form
homopentamer
channel
poor
ion
select
partial
inhibit
drug
hma
micromolar
affin
verdiabaguena
et
al
wilson
gage
ewart
noe
hma
etm
suggest
presenc
two
bind
site
end
tm
domain
ntermin
domain
exhibit
largest
chemic
shift
rel
intens
hma
proton
crosspeak
indic
hma
etm
stoichiometri
ntermin
bind
site
near
suggest
one
hma
molecul
per
etm
pentam
consist
poreblock
inhibit
mode
similar
amt
case
hma
molecul
may
stabil
hydrogen
bond
network
side
chain
sarscov
e
cyclohexamethylen
ring
point
away
center
channel
fig
ctermin
tm
domain
near
hma
etm
stoichiometri
suggest
site
rapid
exchang
chemic
shift
timescal
etmbound
micellebound
form
hma
locat
amilorid
group
hma
like
involv
interact
guanidinium
group
fig
result
confirm
use
extend
peptid
e
mix
sdsdpc
molar
ratio
micel
addit
hma
perturb
residu
cluster
near
ntermin
end
tm
domain
eg
ctermin
end
tm
affect
suggest
interact
hma
report
previous
may
artifact
due
use
etm
peptid
case
result
suggest
similar
behaviour
hmato
protein
protein
ie
presenc
two
bind
site
one
porebind
one
surfacebind
tm
domain
structur
provid
possibl
rational
inhibit
platform
futur
structurebas
drug
design
potenti
pharmacolog
target
small
hydrophob
sh
protein
found
human
respiratori
syncyti
viru
hrsv
envelop
pneumoviru
paramyxovirida
famili
hrsv
lead
caus
bronchiol
pneumonia
infant
elderli
dowel
et
al
frequent
caus
hospit
infant
young
children
industri
countri
develop
countri
hrsv
signific
caus
death
global
estim
death
young
children
hrsv
third
import
caus
deadli
childhood
pneumonia
streptococcu
pneumonia
haemophilu
influenza
nair
et
al
sever
compound
target
rsv
fusion
f
protein
facilit
viral
entri
host
cell
membran
zhao
singh
malashkevich
figur
bind
hma
sarscov
etm
pentamer
channel
pervushin
et
al
side
view
bind
hma
vicin
side
chain
amino
acid
interact
hma
shown
use
stick
represent
b
bind
hma
ctermin
bind
site
channel
vicin
clariti
one
etm
monom
remov
kim
format
bundl
dougla
et
al
lambert
et
al
pastey
gower
spearman
crow
graham
razinkov
gazumyan
nikitenko
ellestad
krishnamurthi
royman
et
al
shepherd
et
al
approach
involv
gene
transfer
expos
viral
protein
cell
kumar
et
al
sirna
specif
viral
protein
zhang
et
al
vaccin
recent
design
base
stabil
rsvf
form
preserv
highli
antigen
site
prefus
state
yield
rsvspecif
neutral
antibodi
mice
macaqu
mclellan
chen
joyc
et
al
mclellan
chen
leung
et
al
recent
vaccin
candid
base
extracellular
domain
ctermin
rsv
viroporin
small
hydrophob
sh
protein
report
schepen
et
al
addit
prevent
nasopulmonari
infect
mice
caus
rsv
report
use
stapl
peptid
target
fusogen
fprotein
bundl
howev
despit
effort
new
fdaapprov
drug
yet
emerg
licens
drug
use
infect
individu
ribavirin
nucleosid
analogu
efficaci
limit
hall
et
al
hrsv
genom
transcrib
protein
collin
melero
one
viroporin
sh
protein
residu
long
depend
subgroup
b
singl
tm
domain
nand
ctermin
extramembran
domain
orient
cytoplasm
lumenallyextracellularli
respect
collin
mottet
gan
et
al
sh
protein
accumul
membran
golgi
complex
infect
cell
also
detect
er
plasma
membran
rixon
et
al
rsv
lack
sh
still
viabl
still
form
syncytia
bukreyev
whitehead
murphi
collin
karron
et
al
techaarpornkul
barretto
peepl
attenu
vivo
mous
rsv
replic
less
effici
upper
respiratori
tract
bukreyev
et
al
wherea
chimpanze
develop
significantli
less
rhinorrhea
infect
wildtyp
rsv
whitehead
et
al
report
shown
lack
sh
protein
lead
attenu
phenotyp
children
rat
jin
et
al
karron
et
al
overal
result
indic
involv
hrsv
sh
protein
replic
pathogenesi
common
sarscov
e
protein
sh
protein
block
delay
apoptosi
infect
cell
fuent
tran
luthra
teng
similar
antiapoptot
effect
sh
protein
observ
member
paramyxovirida
famili
eg
j
paramyxoviru
jpv
jack
boyl
eaton
wang
li
et
al
mump
viru
muv
parainfluenza
viru
formerli
known
simian
viru
system
sh
protein
seem
block
apoptosi
infectionat
least
partthrough
inhibit
pathway
fuent
et
al
li
et
al
lin
bright
rothermel
wilson
fuent
et
al
mutual
orient
tm
form
ion
channel
determin
lipid
bilay
use
sitespecif
infrar
dichroism
gan
ng
xin
gong
torr
descript
fulllength
rsv
sh
protein
monom
obtain
solut
nmr
dpc
micel
gan
et
al
later
bicel
extramembran
domain
like
sarscov
e
rsv
sh
protein
form
homopentamer
channel
gan
et
al
gan
et
al
low
ion
select
tm
domain
sh
protein
funnellik
architectur
gan
et
al
observ
viroporin
eg
iav
schnell
chou
sarscov
e
pervushin
et
al
hcv
ouyang
et
al
narrow
region
gan
et
al
tm
domain
line
hydrophob
side
chain
wherea
open
ntermin
region
line
polar
residu
ie
tm
extend
ctermin
region
follow
loop
wherea
ntermin
cytoplasm
extramembran
domain
form
short
residu
present
micel
bicel
one
compound
pyroninb
report
inhibit
channel
activ
sh
protein
compound
obtain
liposomebas
fluoresc
assay
test
purifi
sh
protein
reconstitut
planar
lipid
bilay
blm
concentr
led
inhibit
channel
activ
kd
effect
pyroninb
test
rsv
replic
vero
cell
tissu
cultur
infect
infect
dose
zero
drug
concentr
nmr
studi
bind
pyroninb
sh
protein
reveal
backbon
reson
perturb
end
tm
domain
ntermin
cytoplasm
end
residu
affect
lumen
ctermin
end
residu
affect
group
nearbi
residu
fig
interestingli
juxtamembran
residu
residu
form
conserv
motif
sh
protein
ilnkl
suggest
critic
region
sh
protein
high
barrier
resist
determin
intermolecular
nuclear
overhaus
effect
noe
drugprotein
complex
possibl
probabl
due
weak
interact
dock
studi
pyroninb
sh
pentamer
model
obtain
dpc
micel
gan
et
al
produc
two
predict
bind
site
end
tm
domain
inde
major
structur
show
drug
locat
near
residu
largest
chemic
shift
perturb
ie
fig
bind
site
near
nterminu
form
one
monom
previou
monom
one
near
cterminu
form
residu
one
monom
previou
monom
fig
similar
druggabl
pocket
sh
pentam
surfac
identifi
use
dogsitescor
volkam
et
al
fig
howev
ctermin
end
tm
domain
residu
suffici
inhibit
sinc
conserv
mutat
almost
complet
prevent
inhibit
inhibit
two
monom
sh
protein
pentam
shown
simplic
druggabl
pocket
green
dark
gray
print
version
mesh
predict
dogsitescor
volkam
kuhn
rippmann
rarey
main
residu
show
largest
nmr
chemic
shift
chang
shown
red
dark
gray
print
version
two
monom
remov
pentam
clariti
vpu
smallmembran
protein
encod
singlestrand
positivesens
rna
human
immunodefici
viru
simian
immunodefici
viru
siv
isol
vpu
one
four
accessori
protein
involv
releas
new
virion
host
cell
membran
cohen
terwillig
sodroski
haseltin
strebel
klimkait
martin
terwillig
cohen
lu
sodroski
haseltin
without
vpu
hiv
particl
fail
detach
plasma
membran
accumul
larg
number
cell
surfac
klimkait
strebel
hoggan
martin
orenstein
initi
structur
studi
vpu
perform
year
ago
solut
nmr
tfewat
use
synthet
peptid
variou
overlap
length
led
model
ntermin
hydrophob
transmembran
helix
tm
domain
ctermin
cytoplasm
domain
helixloophelix
arrang
review
recent
opella
structur
similar
vpu
suggest
vpu
could
form
pore
maldarelli
chen
willey
strebel
later
shown
cationselect
channel
activ
ewart
sutherland
gage
cox
schubert
et
al
uniqu
structur
model
vpu
oligom
defin
review
radoic
lu
opella
analysi
vpu
tm
residu
solidst
nmr
membran
combin
analyt
centrifug
measur
deterg
produc
data
compat
varieti
oligom
coexist
micel
phospholipid
bilay
lu
sharp
ghirlando
yau
tycko
led
propos
regul
viru
releas
vpu
might
involv
alter
plasma
membran
potenti
support
reduc
rate
viru
releas
membran
depolar
hsu
han
shinlapawittayatorn
deschen
ii
observ
reduct
viral
load
viral
pathogen
vpu
tm
domain
scrambl
context
simianhuman
immunodefici
viru
shiv
hout
et
al
iii
substitut
histidin
render
infect
suscept
rim
hout
et
al
howev
recent
studi
challeng
model
argu
critic
involv
vpu
ion
channel
activ
vpuenhanc
viru
releas
inde
mutat
vpu
tm
domain
affect
channel
activ
impair
abil
enhanc
viru
releas
wherea
mutat
affect
viru
releas
retain
ion
channel
activ
bolduan
et
al
thu
function
signific
vpu
ion
channel
activ
hiv
replic
role
target
channel
inhibitor
remain
unclear
sever
viroporin
limit
structur
data
avail
channel
inhibitor
report
follow
section
briefli
describ
three
viroporin
alphaviru
protein
polyomaviru
agnoprotein
protein
found
picornavirus
protein
amino
acid
long
one
predict
tm
domain
viroporin
found
sever
member
alphaviru
genu
positivesens
rna
famili
togavirida
includ
exampl
equin
enceph
virus
chikungunya
viru
sindbi
viru
semliki
forest
virus
sfv
ross
river
viru
rrv
barmah
forest
viru
bfv
virus
structur
protein
translat
er
subgenom
mrna
singl
polyprotein
later
cleav
proteas
order
strauss
strauss
protein
first
describ
earli
welch
sefton
express
e
coli
caus
increas
membran
permeabl
wherea
eukaryot
cell
promot
viral
bud
sanz
perez
carrasco
protein
rrv
bfv
form
cationselect
ion
channel
planar
lipid
bilay
melton
et
al
suggest
role
viroporin
alphaviru
infect
sinc
increas
permeabl
cell
monoval
cation
follow
bud
virion
whatev
mechan
protein
import
role
viru
assembl
bud
exampl
sindbi
viru
cysteineless
mutant
dramat
reduc
releas
viru
particl
lead
aberr
envelop
particl
contain
multipl
nucleocapsid
gaedigknitschko
ding
levi
schlesing
result
consist
indirect
role
pack
viru
spike
glycoprotein
mutat
result
defect
bud
revert
contain
two
addit
mutat
ectodomain
viru
glycoprotein
ivanova
lustig
schlesing
delet
fulllength
cdna
clone
sfv
result
dramat
reduct
viru
releas
liljestrom
lusa
huylebroeck
garoff
bhk
cell
express
strain
produc
thermolabil
particl
suggest
disrupt
glycoprotein
pack
loewi
smyth
von
bonsdorff
liljestrom
schlesing
despit
investig
specif
role
channel
activ
process
still
uncertain
agnoprotein
acid
long
membran
protein
one
predict
tm
domain
requir
product
replic
human
polyomaviru
jcv
john
cunningham
viru
jcv
caus
progress
multifoc
leukoencephalopathi
fatal
demyelin
diseas
result
lytic
infect
oligodendrocyt
agnoproteini
also
found
polyomavirus
includ
bk
viru
simian
viru
sariy
sariba
white
safak
agnoprotein
shown
play
import
regulatori
role
jcv
replic
cycl
elli
dang
norton
koralnik
elli
norton
dang
koralnik
sariba
et
al
possess
properti
commonli
associ
viroporin
suzuki
et
al
suzuki
orba
malcino
et
al
suzuki
orba
okada
et
al
exampl
delet
mutant
defect
virion
releas
viral
propag
also
agnoprotein
local
er
earli
stage
infect
also
found
plasma
membran
late
infect
final
agnoprotein
integr
membran
protein
form
homooligom
enhanc
permeabl
cell
hygromycin
b
induc
influx
extracellular
ca
lead
membran
dysfunct
enhanc
viru
releas
solut
nmr
structur
synthet
peptid
correspond
tm
domain
avail
uncertain
oligomer
size
lipid
bilay
coric
et
al
protein
character
viroporin
still
infanc
protein
residu
long
nonstructur
protein
found
enterovirus
see
ao
sun
guo
recent
review
eg
polioviru
agirr
barco
carrasco
nieva
enterovirus
belong
singlestrand
positivesens
rna
picornavirida
famili
includ
polioviru
coxsacki
viru
human
enteroviru
singl
open
read
frame
encod
peptid
chain
divid
three
region
protein
one
product
polypeptid
region
two
tm
domain
one
hydrophob
de
jong
et
al
nieva
agirr
nir
carrasco
cand
ntermini
polioviru
protein
expos
er
golgi
lumen
express
cell
de
jong
et
al
protein
coxsacki
viru
adopt
opposit
orient
abe
et
al
van
kuppeveld
galama
zoll
van
den
hurk
melcher
polioviru
protein
found
increas
concentr
free
calcium
cytosol
propos
promot
viral
replic
repress
antivir
immun
respons
host
cell
aldab
irurzun
carrasco
howev
precis
structur
data
yet
avail
protein
oligom
one
common
specif
effect
viroporin
channel
activ
may
associ
observ
abil
virus
activ
host
inflammasom
activ
produc
proinflammatori
cytokin
eg
effect
shown
mani
case
caus
disrupt
cellular
ion
homeostasi
allow
ion
leakag
intracellular
organel
cytosol
express
viroporin
review
guo
jin
zhi
yan
sun
exampl
iav
activ
inflammasom
result
h
ion
flux
golgi
mediat
ion
channel
ichinoh
pang
iwasaki
protein
sever
picornavirus
includ
encephalomyocard
viru
emcv
polioviru
enteroviru
human
rhinoviru
triantafil
kar
van
kuppeveld
triantafil
shown
induc
cytoplasm
reloc
inflammasom
activ
intracellular
ca
mediat
manner
ito
yanagi
ichinoh
channel
activ
sarscov
e
protein
requir
process
nieto
requir
activ
channel
activ
sh
protein
may
also
result
directli
indirectli
activ
inflammasom
segovia
et
al
triantafil
kar
vakaki
kotecha
triantafil
case
therefor
develop
channel
inhibitor
improv
patholog
effect
host
inflamm
caus
virus
apart
effect
channel
activ
viroporin
involv
mani
proteinprotein
interact
ppi
suscept
therapeut
intervent
may
increasingli
import
interact
properli
character
see
recent
review
fischer
li
mahato
wang
chen
fischer
et
al
nieva
carrasco
exampl
cytoplasm
region
import
proper
viru
assembl
interact
chen
leser
jackson
lamb
imai
kawasaki
odagiri
imai
watanab
ninomiya
obuchi
odagiri
mccown
pekosz
propos
attract
drug
target
also
hcv
interact
viral
structur
nonstructur
protein
import
promot
viru
assembl
releas
gentzsch
et
al
haqshena
dong
ewart
bowden
gowan
pietschmann
et
al
sakai
et
al
yi
yate
lemon
function
relat
capsid
assembl
local
sever
viral
protein
affect
either
channelinactiv
mutat
treatment
rim
tedburi
et
al
wozniak
et
al
eg
transfer
hcv
core
protein
lipid
droplet
er
depend
interact
boson
granio
bartenschlag
cosset
therefor
disrupt
interact
would
requir
action
ppi
modul
rather
channel
inhibitor
interact
partner
e
sh
protein
review
recent
torr
surya
li
liu
case
cov
e
protein
interact
protein
long
report
contribut
local
virion
format
cors
macham
hogu
macham
ilk
egels
sleytr
lim
liu
siu
et
al
vennema
et
al
recent
report
highlight
interact
protein
associ
lin
seven
teoh
et
al
syntenin
pdz
domain
e
protein
consist
alter
lung
epithelia
integr
inflamm
observ
cov
infect
disrupt
pathway
may
clear
therapeut
implic
sinc
sarscovinfect
patient
exacerb
inflammatori
respons
lead
epitheli
endotheli
damag
edema
acut
respiratori
distress
syndrom
smit
et
al
notic
sever
virus
eg
human
papillomaviru
influenza
found
enhanc
pathogenesi
protein
contain
pdz
bind
motif
review
javier
rice
suggest
particular
case
wide
use
viral
strategi
vpu
known
abil
degrad
hivreceptor
bour
strebel
requir
interact
vpu
cytoplasm
domain
mcnatt
zang
bieniasz
singh
et
al
probabl
tm
domain
et
al
bonifacino
two
protein
may
even
requir
format
oligom
even
less
channel
activ
vpu
also
affect
viru
releas
via
interact
interferoninduc
protein
tetherin
miyagi
andrew
kao
strebe
neil
zang
bieniasz
skasko
et
al
van
damm
et
al
interferoninduc
host
protein
inhibit
releas
mani
envelop
virus
tether
virion
cell
surfac
review
strebel
anoth
case
interact
rsv
sh
g
protein
report
previous
infect
cell
low
tan
ng
tan
sugru
rixon
brown
murray
sugru
although
signific
clear
yet
bcell
receptorassoci
protein
recent
report
interact
sh
protein
although
interact
report
infect
cell
could
prevent
cleavag
format
proapoptot
fragment
thu
delay
apoptosi
infect
cell
interact
also
observ
viroporin
highrisk
human
papillomaviru
similarli
thought
regul
apoptosi
regan
laimin
jcv
agnoprotein
shown
interact
number
cellular
viral
protein
gerit
moen
gerit
et
al
howev
despit
intens
research
exact
regulatori
function
agnoprotein
viral
replic
fulli
understood
jcv
agnoprotein
specif
interact
adaptor
protein
complex
delta
subunit
interact
interrupt
adaptor
protein
complex
vesicular
traffick
protein
target
lysosom
degrad
pathway
allow
transport
agnoprotein
plasma
membran
find
suggest
viroporin
virus
may
also
highli
regul
specif
interact
host
cell
protein
suzuki
et
al
patholog
relev
interact
viroporin
associ
viral
host
protein
present
attract
therapeut
target
disrupt
small
molecul
well
peptid
stabil
intern
coval
linkag
stapl
peptid
walenski
bird
principl
transmembran
extramembran
domain
viroporin
potenti
templat
peptidebas
modul
exampl
one
could
design
stapl
peptid
mimick
cytoplasm
domain
sh
protein
disrupt
interact
sh
variant
death
effector
domain
vded
would
lead
enhanc
apoptosi
cell
death
infect
cell
one
could
also
mimic
transmembran
domain
disrupt
monomermonom
interact
shown
recent
halobacterium
salinarum
efflux
small
multidrug
resist
protein
inhibit
peptid
target
tm
domain
bellmannsickert
stone
poulsen
deber
case
viroporin
disrupt
oligomer
statu
would
abolish
channel
activ
classic
strategi
revisit
differ
approach
howev
detail
mechanist
inform
avail
conceptu
strategi
wide
use
